GleamWall
中文EN

PCVX Vaxcyte, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649094 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-74.8%
TTM EPS YoY-66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.7%
ROA-37.3%
ROIC (approx.)-39.1%
Asset turnover—

Leverage & solvency

Liabilities / assets16.7%
Debt / equity0.00x
Current ratio4.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$794.31M$476.64M
SG&A expense$129.37M$92.90M
Operating income-$923.67M-$569.55M
Interest expense—$0
Income tax$0$0
Net income-$766.63M-$463.93M
EBITDA-$907.28M-$562.54M
EPS (basic)-5.63-3.80
EPS (diluted)-5.63-3.80
Dividends declared per share0.000.00
Weighted avg. shares (diluted)136.09M122.00M
Balance sheet
Cash & equivalents$173.96M$389.19M
Short-term investments$1.39B$1.36B
Current assets$1.63B$1.79B
PP&E, net$257.37M$198.04M
Total assets$3.00B$3.51B
Current liabilities$205.75M$140.18M
Total liabilities$317.21M$205.50M
Shareholders' equity$2.69B$3.31B
Shares outstanding131.06M124.89M
Cash flow statement
Operating cash flow-$655.58M-$452.63M
Capital expenditure$13.71M$22.43M
Free cash flow-$669.29M-$475.05M
Investing cash flow$437.35M-$2.01B
Financing cash flow$2.01M$2.45B
Depreciation & amortization$16.40M$7.00M
Stock-based compensation$138.84M$84.82M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.